{"id":9588,"date":"2021-04-14T23:00:00","date_gmt":"2021-04-14T23:00:00","guid":{"rendered":""},"modified":"2021-04-14T23:00:00","modified_gmt":"2021-04-14T23:00:00","slug":"adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma-eortc-1325-mg-keynote-054-health-related-quality-of-life-results-from-a-double-blind-randomised-controlled-phase-3-trial","status":"publish","type":"post","link":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/2021\/04\/14\/adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma-eortc-1325-mg-keynote-054-health-related-quality-of-life-results-from-a-double-blind-randomised-controlled-phase-3-trial\/","title":{"rendered":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial."},"content":{"rendered":"<p>The European Organisation for Research and Treatment of Cancer (EORTC) 1325-MG\/KEYNOTE-054 trial in patients with resected, high-risk stage III melanoma demonstrated improved recurrence-free survival with adjuvant pembrolizumab compared with placebo [&#8230;]\n","protected":false},"excerpt":{"rendered":"<p>The European Organisation for Research and Treatment of Cancer (EORTC) 1325-MG\/KEYNOTE-054 trial in patients with resected, high-risk stage III melanoma demonstrated improved recurrence-free survival with adjuvant pembrolizumab compared with placebo &#8230;<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[510],"tags":[],"acf":[],"_links":{"self":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts\/9588"}],"collection":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/comments?post=9588"}],"version-history":[{"count":0,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts\/9588\/revisions"}],"wp:attachment":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/media?parent=9588"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/categories?post=9588"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/tags?post=9588"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}